Tesaro, AnaptysBio enter into license deal for multiple immuno-oncology programs
As part of the deal, Tesaro will receive rights to monospecific antibody drug candidates targeting
Therapeutic antibodies selected from these programs will form the basis of a strategic platform that will allow Tesaro to develop new monotherapy and
Antibody candidates from these programs will enter clinical trials over the next 18 to 24 months.
Tesaro president Mary Lynne Hedley said the agreement provides the company with a basis from which to develop novel therapeutics, including
«These antibody candidates are being developed to address some of the most validated and promising targets in
«We are also interested in evaluating combinations of these antibodies with
First clinical trial under the deal is expected to start in
As part of the deal, TESARO will pay an upfront license fee of $17m, as well as provide funding of costs incurred by AnaptysBio related to the development programs.
For each development program, AnaptysBio is eligible to get milestone payments of $18m if certain research and development events are achieved and an additional $90m related with certain US and
AnaptysBio will also be eligible to get tiered
Both the firms will jointly complete preclinical development of the antibody candidates, with Tesaro being solely responsible for all clinical development, manufacturing, regulatory and commercial activities.
AnaptysBio president and CEO Hamza Suria said the company’s
«In addition to selecting for antibodies with optimal checkpoint antagonist function, our mammalian cell display system permits simultaneous selection for high antibody expression, stability and robust biophysical features required for successful development and ideal pharmacokinetic properties," Suria said.